Lupin signs agreement with AbbVie for MALT1 inhibitor programme

Lupin has tied up with – AbbVie – a global biopharmaceutical company to develop new drugs. AbbVie has signed an agreement to get license rights for Lupin’s MALT1 (Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1) inhibitor programme.

The move will help AbbVie which is working on drugs to inhibit haematological cancers which has limited treatment options as MALT-1 is a protein involved in T-cell and B-cell lymphocyte activation.

Company Profile : Lupin Ltd

Be the first to comment

Leave a Reply

Your email address will not be published.